Novartis Signs Option to Buy Selexys for up to $665 Million

September 19, 2012

We represented long-time client Novartis in its exclusive option to acquire Selexys Pharmaceuticals Corp. and its lead asset, monoclonal antibody SelG1, for up to $665 million.

The Oklahoma City-based Selexys is developing drugs to treat chronic inflammatory and thrombotic diseases such as Crohn's disease, ulcerative colitis, rheumatoid arthritis, psoriasis and others.

Adam Golden led a team that included Diane Frankle, Laurie Abramowitz and Joe Berkowitz.

Email Disclaimer